Navigation Links
Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2012

BETHESDA, Md., Aug. 6, 2012 /PRNewswire-Asia/ -- Chindex International, Inc. (NASDAQ: CHDX), an American health care company providing health care services in China through the operations of United Family Healthcare, a network of private primary care hospitals and affiliated ambulatory clinics, today announced financial results for the second quarter and first half of 2012 ended June 30, 2012.

Second Quarter 2012 Financial Highlights

  • Revenue from healthcare services increased 33% to $39.1 million from $29.5 million in the prior year period.
  • Adjusted EBITDA rose by 33% to $7.7 million, from Adjusted EBITDA of $5.8 million in the prior year period.
  • Income from operations was $3.4 million, unchanged from the prior year period.
  • Net income was $1.8 million, or $0.11 per diluted share, compared to net income of $2.9 million, or $0.17 per diluted share, in the prior year period.
  • Development, pre-opening and start-up expense was $2.5 million compared to $1.2 million in the prior year period.
  • Roberta Lipson, President and CEO of Chindex, commented, "We are pleased that we recorded outstanding top-line results for the second quarter as revenue grew 33% year-over-year to nearly $40 million. Contributions came mainly from our existing and newly expanded facilities and our ongoing geographic expansion. Adjusted EBITDA in the quarter reached $7.7 million, representing a 20% margin. Both revenue and adjusted EBITDA exceeded the Company's previously-announced guidance. As expected, our GAAP bottom-line was again impacted by significant development expenses, which for the second quarter amounted to $2.5 million, plus a provision for income tax of $1.7 million, as we continue to expand and ramp up operations in Beijing and Tianjin."

    "During the quarter we inccile net loss to net cash provided by operating activities:Depreciation and amortization

    3,4712,194Inventory write down

    383Provision for doubtful accounts - healthcare services

    1,396930Loss on disposal of property and equipment

    677Equity in income of unconsolidated affiliate

    (212)(582)Deferred income taxes

    92(1,454)Stock based compensation

    1,6011,668Foreign exchange loss (gain)

    242(257)Amortization of debt issuance costs

    55Amortization of debt discount

    124124Changes in operating assets and liabilities:Restricted cash

    -300Accounts receivable

    (5,182)(2,101)Receivables from affiliates

    (1,069)8,898Inventories of supplies

    200(260)Other current assets and other assets

    (514)724Accounts payable, accrued expenses, other current liabilities and deferred revenue

    2,173339Payable to affiliates

    2,4192,899Income taxes payable

    119570Net cash provided by operating activities

    6,18815,790INVESTING ACTIVITIESPurchases of short-term investments and CDs

    -(21,271)Proceeds from redemption of CDs

    26,52622,837Purchases of property and equipment

    (14,968)(11,157)Net cash provided by (used in) investing activities

    11,558(9,591)FINANCING ACTIVITIESRestricted cash for sinking funds

    (10,968)-Restricted cash for Exim loan collateral

    (8,664)-Repurchase of restricted stock for income tax withholding

    (98)-Proceeds from exercise of stock options and warrants

    16114Net cash (used in) provided by financing activities

    (19,714)114Effect of foreign exchange rate changes on cash and cash equivalents

    (163)263Net increase in cash and cash equivalents

    (2,131)6,576Cash and cash equivalents at beginning of period

    33,75532,007Cash and cash equivalents at end of period

    38,583Supplemental disclosures of cash flow information:Cash paid for taxes

    2,973Non-cash investing and financing activities consist of the following:Change in property and equipment purchases included in accounts payable


     The table below reconciles our consolidated net income to Adjusted EBITDA (in thousands)Three months ended June 30,Six months ended June 30,2012201120122011Consolidated net income 




    $1,713Adjustments:Depreciation and amortization




    2,194Provision for income taxes




    2,062Interest expense




    181Interest and other income, net




    -293Development, pre-opening and start-up expense




    2,047Equity in earnings of unconsolidated affiliate




    -582Non-recurring charges for CML JV formation







    6,009Adjusted EBITDA





    reased the number of available beds at Beijing United Family Hospital's main campus to 70 from 41 in the previous quarter. With much of the new state-of-the-art equipment installed and our new operating rooms, we are confident of increasing patient flow at our home base in Beijing. Also encouragingly, our capacity and service offerings of UFH facilities in Tianjin and Shanghai continued to experience strong growth and show great development potential."

    Revised Guidance"Looking forward to the remainder of the year, we believe Chindex will continue benefitting from favorable policies, growing market demand, and revenue acceleration from our expanded facilities and services," Ms. Lipson continued. "For the full year of 2012, we expect revenue to grow at a percentage rate in the high-twenties to low-thirties, compared to the previous guidance in the mid-twenties. This revised guidance reflects the strong momentum built up over the first half of 2012 and our positive outlook for the remainder of the year based on continuing strong demand at our existing facilities and increasing contributions from our new facilities and expanded service offerings. We expect adjusted EBITDA margin for the full year to continue at an upper-teen percentage, compared to previous guidance of a mid-teen rate."

    Second Quarter 2012 Financial ResultsSecond quarter 2012 revenue from healthcare services increased 33% to $39.1 million from $29.5 million in the prior year period. These results reflect continued growth of inpatient and outpatient volume across the United Family Healthcare network as well as nascent contributions from the phased expansion of the Company's flagship hospital in Beijing. Outpatient services contributed 59% and inpatient services contributed 41% of revenue, in line with the prior year period. By service line, surgical services contributed 21.1%, OB/GYN contributed 13.5%, pediatrics contributed 7.5%, ancillary services contributed 31.9% and other clinical service lines contributed 26.0% of revenue.

    Operating expenses for the three months ended June 30, 2012 increased 37% to $35.8 million from $26.1 million in the prior year period. These costs were primarily driven by the Company's recently opened expansions as well as development of future facilities. Salaries, wages and benefits in the second quarter of 2012 increased 37% to $21.3 million from $15.5 million in the prior year period, reflecting a 35% increase in headcount to support revenue growth and development activities, including some newly recruited talent now on-board for the Company's Rehabilitation Hospital which is now under construction. Development, pre- and post-opening and start-up expenses related to facilities (including the new Beijing United Family Rehabilitation Hospital, the ramp-up at Tianjin United Family and new facilities expansion at Beijing United and Shanghai Pudong) were $2.5 million this quarter, compared to $1.2 million for the prior year period. Operating expenses also included certain non-cash expenses including $987,000 of stock-based compensation expense compared to $466,000 for the prior year period.

    Adjusted EBITDA in the second quarter of 2012 increased 33% to approximately $7.7 million versus $5.8 million in the prior year period. The Adjusted EBITDA margin in the current period was 20%, exceeding the Company's target levels. The Adjusted EBITDA results illustrate the consistent profitability and expanding earnings base of existing UFH facilities.

    Income from operations was $3.4 million, unchanged from the prior year period.

    The Company recorded a $1.7 million provision for taxes in the second quarter of 2012 compared to $1.3 million in the prior year period. As in past quarters, the current period provision continued to be  heavily impacted by losses in development and start-up entities for which the Company cannot currently recognize tax benefits.

    Net income for the quarter ended June 30, 2012 was $1.8 million, or $0.11 per diluted share, compared to net income of $2.9 million, or $0.17 per diluted share, in the prior year period. For the second quarter of 2012, weighted average diluted shares outstanding were 17.4 million.

    As of June 30, 2012, the Company had $31.6 million in unrestricted cash, cash equivalents and investments.

    First Half 2012 Financial ResultsDuring the first half of 2012, revenue from healthcare services increased 33% to $71.6 million from $53.7 million in the prior year period, reflecting growing inpatient and outpatient volume across the United Family Healthcare network. Outpatient services contributed 60% of revenue and inpatient services contributed 40% of revenue in the first half of 2012 unchanged from the ratios of the first half of 2011. By service line, surgical services contributed 20.1%, OB/GYN contributed 14.2%, pediatrics contributed 7.6%, ancillary services contributed 32.6% and other services contributed 25.5% of revenue.

    Operating expenses for the first half of 2012 increased 34% to $67.6 million from $50.6 million in the prior year period. Development, pre-opening and start up expenses rose to $5.7 million from $2.0 million in the prior year period primarily as a result of expenses related to the Company's Beijing, Pudong, and Tianjin projects. Operating expenses also included certain non-cash expenses including $1.6 million of non-cash stock compensation expense compared to $1.7 million for the prior year. Income from operations increased 29% to $4.0 million compared to income from operations of $3.1 million in the prior year period. Adjusted EBITDA was approximately $13.2 million compared to $7.7 million in the prior year period. 

    Provision for taxes was $3.0 million compared to $2.1 million in the prior year period. Net income was $1.3 million, or $0.08 per diluted share, compared to net income of $1.7 million, or $0.11 per diluted share, in the first half of 2011. For the first half of 2012 ended June 30, 2012, weighted average diluted shares outstanding were 17.5 million.

    Chindex Medical Limited The Chindex Medical Limited joint venture (CML) between Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma") and Chindex International began operations on January 1, 2011. This strategic venture merged the former Medical Products division of Chindex International and select medical device companies of Fosun Pharma. Fosun Pharma owns 51% and Chindex owns 49% of the CML joint venture. Chindex recognizes its 49% interest in CML's net income using the equity method of accounting.

    For the second quarter and first half of 2012 ended June 30, 2012, Chindex recognized income of $114,000 and $212,000, respectively, for its 49% equity in the operating results of CML. This consisted of income of $243,000 and $469,000, respectively, for the stand-alone net income of CML (after recognition of stock-based compensation expense) and after deducting $129,000 and $257,000, respectively, for the amortization of basis differences attributable to acquired intangibles.

    Non-GAAP MeasuresThe Company presents Adjusted EBITDA to better illustrate ongoing operational results. Adjusted EBITDA is defined as income (loss) before interest expense, interest and other income, income taxes, depreciation and amortization, and also excludes development, pre-opening and start-up expenses related to new and pending hospitals and clinics, equity in earnings (loss) income of unconsolidated affiliate, non-recurring charges for Chindex Medical Limited (CML) joint venture formation and effect of change in corporate cost allocations. The Company anticipates recurring development, pre-opening and start-up expense and notes that such expense is a basic element of the long term growth plan. Management believes that providing an Adjusted EBITDA analysis to investors is a helpful metric to better illustrate the Company's operations, including development plans, and changes in presentation from historical periods. The Company uses Adjusted EBITDA for business planning and other purposes. Other companies may calculate Adjusted EBITDA differently, and therefore Chindex's Adjusted EBITDA may not be comparable to similarly titled measures of other companies. Adjusted EBITDA is not a measure of financial performance under U.S. generally accepted accounting principles (GAAP), and should not be considered in isolation or as an alternative to net income (loss), cash flows from operating activities and other measures determined in accordance with GAAP. Items excluded from Adjusted EBITDA are significant and necessary components to the operations of the Company's business, and, therefore, Adjusted EBITDA should only be used as a supplemental measure of operating performance.

    Conference Call Management will host a conference call at 8:00 am ET Tuesday morning on August 7, 2012 to discuss financial results. To participate in the conference call, U.S. domestic callers may dial 1-877-303-9231 and international callers may dial 1-760-666-3567 approximately 10 minutes before the conference call is scheduled to begin.  A telephone replay will be available from the day of the call until August 14, 2012 by dialing (U.S. domestic) 1-855-859-2056 or (international) 1-404-537-3406, passcode 14215732. A webcast of the earnings call will be accessible via Chindex's website at Chindex International, Inc.Chindex is an American health care company providing health care services in China through the operations of United Family Healthcare, a network of private primary care hospitals and affiliated ambulatory clinics. United Family Healthcare currently operates in Beijing, Shanghai, Tianjin and Guangzhou. The Company also provides medical capital equipment and products through Chindex Medical Ltd., a joint venture company with manufacturing and distribution businesses serving both domestic China and export markets. With thirty years of experience, the Company's strategy is to continue its growth as a leading integrated health care provider in the Greater China region. Further company information may be found at the Company's website at

    Safe Harbor Statement Statements made in this press release relating to plans, strategies, objectives, economic performance and trends and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, the factors set forth under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the twelve months ended December 31, 2011, updates and additions to those "Risk Factors" in the Company's interim reports on Form 10-Q, Forms 8-K and in other documents filed by us with the Securities and Exchange Commission from time to time. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential," or "continue" or similar terms or the negative of these terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance or achievements. The Company has no obligation to update these forward-looking statements.


    ICR, Inc.
    Robert Koepp
    (+86) 10-6583-7516
    (646) 328-25Financial Summary Attached

     CHINDEX INTERNATIONAL, INC.CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS(in thousands except share and per share data)(Unaudited)Three months ended June 30,Six months ended June 30,2012201120122011Healthcare services revenue

    53,650Operating expensesSalaries, wages and benefits

    21,30915,47339,92530,228Other operating expenses

    5,3454,23710,1098,556Supplies and purchased medical services

    4,8123,2279,0505,862Bad debt expense

    6304981,395930Depreciation and amortization

    1,8201,0573,4712,194Lease and rental expense

    1,8341,5993,6872,79935,75026,09167,63750,569Income from operations 

    3,3673,3743,9923,081 Other income and (expenses)Interest income

    134218273360Interest (expense)

    (91)(78)(215)(181)Equity in income (loss) of unconsolidated affiliate

    114729212582Miscellaneous income (expense)  - net

    10(25)-(67)Income before income taxes

    3,5344,2184,2623,775Provision for income taxes

    (1,724)(1,275)(2,983)(2,062)Net income

    ,713Net income per common share - basic

    $.11$.18$.08$.11Weighted average shares outstanding - basic

    16,317,84116,129,32816,304,81616,102,735Net income per common share - diluted

    $.11$.17$.08$.11Weighted average shares outstanding - diluted


     CHINDEX INTERNATIONAL, INC.CONSOLIDATED CONDENSED BALANCE SHEETS(in thousands except share data)(Unaudited)June 30, 2012December 31, 2011ASSETSCurrent assets:Cash and cash equivalents


    -26,394Accounts receivable, less allowance for doubtful accounts of $9,662and $8,300. respectively

    17,66213,947Receivables from affiliates

    12,05310,984Inventories of supplies, net

    2,0612,307Deferred income taxes

    3,5313,887Other current assets

    5,1044,652Total current assets

    72,03595,926Restricted cash and sinking funds 


    -100Investment in unconsolidated affiliate

    33,77533,728Property and equipment, net

    77,03065,465Noncurrent deferred income taxes

    674424Other assets

    2,7262,719Total assets

    99,392LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable 

    3,957Payable to affiliates

    11,8229,404Accrued expenses

    11,43311,735Other current liabilities

    7,0475,549Income taxes payable 

    2,2532,141Total current liabilities

    37,90632,786Long-term debt and convertible debentures

    23,90323,818Long-term deferred tax liability

    288287Total liabilities

    62,09756,891Commitments and contingenciesStockholders' equity:Preferred stock, $.01 par value, 500,000 shares authorized, none issued

    --Common stock, $.01 par value, 28,200,000 shares authorized, including 3,200,000 designated Class B:Common stock – 15,886,890 and 15,652,917 shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively



    157Class B stock – 1,162,500 shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively



    12Additional paid-in capital

    120,447118,930Retained earnings 

    15,77014,491Accumulated other comprehensive income

    8,4138,911Total stockholders' equity

    144,801142,501Total liabilities and stockholders' equity


    ,713Adjustments to recon

    SOURCE Chindex International, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Chindex International, Inc. to Report First Quarter 2012 Financial Results
    2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
    3. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
    4. VWR International, LLC Signs Agreement to Acquire basan Germany GmbH
    5. Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research
    6. SurgLine International, Inc. Chief Executive Officer, Thomas Toland, Exclusive Interview on Stock Traders Talk Radio
    7. SurgLine International, Inc. to Expand its Trauma Product Line With Completion of Acquisition
    8. DATATRAK International, Inc. to Webcast, Live, at on July 12th
    9. DATATRAK International, Inc. Investor Presentation Now Available for On-demand Viewing at
    10. BioMed Diagnostics Microbiology Diagnostic Devices Now Available Worldwide Through Distribution Agreement With VWR International, LLC
    11. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    Post Your Comments:
    (Date:10/8/2015)... and PITTSBURGH , Oct. 8, 2015 ... global pharmaceutical company, will host a conference call and ... pm ET to review the value to be created ... ; TASE) through Mylan,s offer to acquire the company. ... which outlines the compelling proposition for Perrigo shareholders. Mylan,s ...
    (Date:10/8/2015)... -- Following months of investigation, Ross Feller Casey , LLP ... the anticoagulant Xarelto,s recommended dosage doesn,t work for as long ... on behalf of a Florida ... didn,t work as the manufacturer suggested. Ross Feller Casey ... behalf of clients from across the country with similar claims. ...
    (Date:10/8/2015)... CHARLOTTE, N.C. , Oct. 8, 2015  Clariant, a ... Healthcare Packaging manufacturing facility in Belen, New ... manufactured for healthcare applications, including desiccant canisters and packets ... Belen plant is the second Clariant site ... – to meet the ISO 15378:2011 standards, following only ...
    Breaking Medicine Technology:
    ... 2012 announces that a new market ... Vaccines - Top 10 Global ... This market research report package offers an in-depth ... future outlook for vaccines in top 10 global ...
    ... HAIKOU, China, March 15, 2012 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, ... the "Company"), a fully-integrated specialty pharmaceuticals company in China, today ... Full Year Highlights , ... from $74.4 million in fiscal year 2010. , Income ...
    Cached Medicine Technology:
    (Date:10/10/2015)... ... ... have to walk with crutches for the rest of my life," said an inventor from ... that would give me more independence and freedom would be amazing. This inspired me to ... developed the STRAP IN to enable an individual to walk with crutches without having to ...
    (Date:10/10/2015)... ... , ... Isabel Healthcare will participate in the Cerner Health Conference October 11-14, ... the Institute of Medicine’s latest report “Improving Diagnosis in Healthcare”, Isabel Healthcare will be ... providers and consumers to potentially reduce the chance of error. The report suggests that ...
    (Date:10/9/2015)... , ... October 09, 2015 , ... ... highly sought after internships at the pre-eminent organization in global health: the World ... eliminating social and health disparities. These internships are a mechanism for WHO to ...
    (Date:10/9/2015)... LINCOLN, R.I. (PRWEB) , ... October 09, 2015 , ... ... (NFPA), working smoke alarms can cut the risk of dying in reported home fires ... safety tips to make sure smoke alarms are property installed and maintained. , Half ...
    (Date:10/9/2015)... ... 09, 2015 , ... On Saturday, September 26, 2015, 48-year-old MS survivor and ... Spain. Representing both the USA and Sweden in the Speed and Power events, which ... Crosses, she was awarded 1 Silver and 4 Gold Medals. , “I remember looking ...
    Breaking Medicine News(10 mins):
    ... Kensey Nash Corporation (Nasdaq: KNSY ) ... New York Emerging Growth Institutional Investor Forum at The ... 24, 2009.Joseph W. Kaufmann, Kensey Nash,s CEO, will deliver ... The presentation materials will be available on the ...
    ... PT. RICHMOND, Calif., March 13 Transcept Pharmaceuticals, Inc. ... focused on the development and commercialization of proprietary products ... neuroscience, today announced it will report results for its ... market close. A conference call to review the results ...
    ... The American Parkinson Disease Association (APDA) and the National ... of Young Onset Parkinson Conferences; First to be held ... 13 The American Parkinson Disease Association,s ... Foundation,s (NPF) Young Onset Parkinson Network announced their first ...
    ... Finding suggests children with language disorders may benefit from ... Musical training enhances the ability to recognize emotion in ... musical training might benefit people with language problems and ... emotion in sound is a skill that translates across ...
    ... smartest decision, report says , , FRIDAY, March 13 (HealthDay ... drug plans available through Medicare don,t select the plan ... The report found that the more than 50 standalone ... the best value for their individual medical and financial ...
    ... Street has earned the number one spot in the ... of Outsourcing Customer Satisfaction Survey, 2008.Andrew DeVoe, CEO and ... recognition from the Health Insurance Industry and all our ... to excellence.""The fact that we have been ranked in ...
    Cached Medicine News:
    Symbia T6, a True Point SPECT·CT system, combines a dual-detector variable angle gamma camera with a six slice CT scanner for advanced oncology, neurology, and cardiology applications....
    ... ACOM.PC turns every standard PC into ... internists, and cardiologists can use their ... access to image data thanks to ... 3 format and the compatible storage ...
    ... Soarian Cardiovascular Enterprise is a comprehensive ... care continuum from admission to follow-up. ... image acquisition, and diagnostic tools from ... provide a single, longitudinal clinical repository ...
    ... accurate lesion assessment plays a ... the appropriate stent size and ... (IC3D), a highly precise three-dimensional ... now able to quickly quantify ...
    Medicine Products: